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ABSTRACT 
 
ERIN A. HOEVELMANN: Pharmacists’ Perceptions of Rapid Diagnostic Testing in 
Community Pharmacies in Mississippi: A Diffusion of Innovations Approach  
(Under the direction of Dr. Donna West-Strum) 
 
Objectives: The broad purpose of this study is to describe community pharmacists’ 
perceptions of rapid diagnostic tests (RDTs) in community pharmacies in Mississippi. 
The focused goal of this study is to determine the correlation between Everett M. Rogers’ 
attributes of the diffusion of innovations (including relative advantage, compatibility, 
complexity, trialability, and observability) and the willingness of community pharmacists 
to offer RDTs in community pharmacies in Mississippi. 
Methods: This study was approved by the University of Mississippi IRB. A list of 
licensed pharmacists was obtained from the Mississippi Board of Pharmacy. An email 
with study details and a link to the Qualtrics® survey was sent to licensed pharmacists. 
The survey included a screening question (to ensure all participants had recent experience 
in a community pharmacy in Mississippi), demographic questions, practice-setting 
questions, several statements for each attribute of the diffusion of innovations, possible 
barriers to and benefits of offering RDTs, and asked participants to rate their willingness 
to offer RDTs. SPSS® was used for data analysis.  
Results: The Qualtrics® survey was sent to 3110 possible respondents. The actual 
response rate was 3.8%. Mean and median ratings were calculated for each of the 
attributes of the diffusion of innovations and for willingness to offer RDTs. A linear 
regression with the mean rating of each attribute of the diffusion of innovations as 
vi 
independent variables/predictors and the mean rating of willingness to offer RDTs as the 
dependent variable/outcome variable was performed.  Relative advantage, complexity, 
and trialability were found to be statistically significant in influencing pharmacists’ 
willingness to offer RDTs. 
Conclusion: The attributes of Rogers’ diffusion of innovations that influence Mississippi 
pharmacists’ willingness to offer RDTs in the community pharmacy include relative 
advantage, complexity, and trialability. As the perceived benefit increases, perceived 
complexity decreases, and degree to which an innovation may be experimented with on a 
limited basis increases, a Mississippi community pharmacist’s willingness to offer RDTs 
increases. As RDTs are more widely implemented in community pharmacies, it will be 
important for pharmacists to see an advantage to offering RDTs, be prepared to 
understand RDTs, and be able to experiment with the implementation of RDTs.
vii 
TABLE OF CONTENTS 
 
LIST OF TABLES...........................................................................................................viii 
INTRODUCTION..............................................................................................................1  
METHODOLOGY...........................................................................................................17 
RESULTS.........................................................................................................................23  
DISCUSSION...................................................................................................................35  
CONCLUSION.................................................................................................................43
BIBLIOGRAPHY.............................................................................................................44 
APPENDIX A: EMAIL INVITATION............................................................................49 
APPENDIX B: QUALTRICS® SURVEY.......................................................................51 
 
 
 
 
 
 
 
 
 
 
 
viii 
LIST OF TABLES 
 
TABLE 1 DIFFUSION OF INNOVATIONS STATEMENTS…………………….20 
TABLE 2 BENEFITS AND CONCERNS STATEMENTS.....…………………….21 
TABLE 3  DEMOGRAPHICS………………………………………………………24 
TABLE 4  PRACTICE SITE………………………………………………………...25 
TABLE 5  DIFFUSION OF INNOVATIONS: ATTRIBUTE STATEMENT 
RATINGS………………………………………………………………..27 
TABLE 6  DIFFUSION OF INNOVATIONS: ATTRIBUTE RATINGS………….29 
TABLE 7  BENEFITS AND CONCERNS: STATEMENT RATINGS………….…29 
TABLE 8 BARRIERS TO OFFERING POINT OF CARE TESTING……….……30 
TABLE 9 BENEFITS OF OFFERING POINT OF CARE TESTING………….….31 
TABLE 10 WILLINGNESS TO OFFER POINT OF CARE TESTING………….....31 
TABLE 11 REGRESSION COEFFICIENTS………………………………………..32 
TABLE 12 DIFFUSION OF INNOVATIONS: STATEMENTS GENERATING 
MEAN RATINGS OF LESS THAN 3……………………………….….36
1 
INTRODUCTION 
Background 
Amidst changes in healthcare policy, the role of the pharmacist as a healthcare 
professional is expanding. What was once considered a profession revolved around 
dispensing and compounding is now evolving into a profession involving collaborating 
with physicians, counseling patients, medication therapy management, medication 
synchronization, and performing rapid diagnostic tests. Rapid diagnostic tests (or RDTs) 
are diagnostic tests designed for use at the point-of-care and are considered low-cost, 
simple to operate and read, specific, and require only a short amount of time to work 
(BIO Ventures for Global Health, 2015). They are also referred to as Point of Care tests. 
These tests involve performing a robust diagnostic test outside of a laboratory near the 
patient. They provide reliable results to aid in disease screening and diagnosis (Gilbreath, 
2016). RDTs are especially useful in impoverished countries and are often utilized to 
diagnose diseases such as malaria. In the United States, RDTs can be used to diagnose 
patients with influenza, Group A streptococcus, HIV, and hepatitis C. Performing these 
tests in the community pharmacy setting affords patients easy access to treatment without 
the high costs often related to primary care visits. 
 
Objectives 
The broad purpose of this study is to describe community pharmacists’ perceptions of 
RDTs in community pharmacies in Mississippi.
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The focused goal of this study is to determine the correlation between Everett M. Rogers’ 
attributes of the diffusion of innovations (including relative advantage, compatibility, 
complexity, trialability, and observability) and the willingness of community pharmacists 
to offer RDTs in community pharmacies in Mississippi. 
 
RDTs and Education 
Dr. Danielle M. Daunais and colleagues (2015) conducted research surrounding the 
adoption of rapid diagnostic tests in pharmacy and published, “Assessment of pharmacy 
students’ and licensed pharmacists’ perceived knowledge, application, and interpretation 
regarding rapid diagnostic tests (RDTs) for infectious diseases.” The study investigates 
the opinions and concerns of pharmacists and pharmacy students regarding the giving of 
and the interpretation of rapid diagnostic tests. 716 respondents, consisting of 194 
pharmacists and 522 pharmacy students, were asked to respond and indicate their 
agreement to statements such as, “I am comfortable discussing RDTs with patients, 
including their value and limitations,” and, “RDTs will become a routine part of 
pharmacy practice.” Only 16.6% of participants agree or strongly agree that they are 
comfortable discussing RDTs with patients, while 45.2% of participants agree or strongly 
agree that RDTs will become a routine part of pharmacy practice.  
 
Pharmacists and pharmacy students recognize the expanding roles of pharmacists and 
believe they will eventually give RDTs as a part of their every day duties. However, as of 
yet, many are neither prepared nor comfortable doing so. 53.7% of respondents disagreed 
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or strongly disagreed with the statement, “I feel my college education adequately 
prepared me to interpret RDTs.” Therefore, one of the largest obstacles preventing 
pharmacists and pharmacy students from performing RDTs is a lack of education on the 
topic. 
 
The majority of pharmacists and pharmacy students indicated that they would attend a 
continuing education (CE) program to learn more about RDTs and their use by 
pharmacists, attend a CE program to improve their physical assessment skills, and/or 
would enroll in a certificate program on RDTs. Therefore, it is not a lack of motivation or 
eagerness that is preventing more pharmacists from administering RDTs; it is simply a 
lack of education, which can easily be resolved in pharmacy schools as indicated by Dr. 
Tolu P. Akinwale and colleagues (2015) in “Pharmacy-based point-of-care testing for 
infectious diseases: Considerations for the pharmacy curriculum.” 
 
Dr. Tolu P. Akinwale and colleagues (2015) developed a curriculum in which pharmacy 
students are taught to perform and read RDTs while gaining practical experience. The 
proposed curriculum involves 750 minutes of contact time as a one-semester hour course. 
This one credit hour course could be implemented into many Pharm.D. programs and 
could greatly diminish the objection pharmacists and pharmacy students have to 
performing RDTs in the pharmacy setting, as a lack of education would no longer be an 
issue. 
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Pharmacists’ Role/Relationship 
Even with solutions to the lack of education regarding RDTs, such as Dr. Tolu P. 
Akinwale and colleagues’ (2015) proposed curriculum, the question arises regarding 
whether or not pharmacists will be utilized to perform RDTs. A study conducted by Dr. 
Marcia M. Worley and colleagues (2007) explored the perceived roles of pharmacists 
from the aspect of both the pharmacist and the patient. The seemingly “traditional roles” 
of the pharmacist were widely recognized and showed no significant differences in 
perceptions between the pharmacist and the patient. These roles included those regarding 
information sharing, specifically talking with patients about how to watch for medication 
side effects, talking with patients even if the patients do not have any medication 
questions, and talking with patients about whether or not it is OK to take their 
medications with over-the-counter products. These are questions asked by pharmacists to 
ensure the safety of patients, and these questions can be asked and discussed during the 
time the patient spends at the cash register. The information-sharing role of the 
pharmacist is consistent with patients’ expectations and pharmacists’ expectations and 
does not require a significant portion of the pharmacists’ time.  
 
Differences in perceptions of the pharmacists’ role arise when the pharmacist adopts roles 
that are more relationship-based. The patient-centeredness of the pharmacist-patient 
relationship is an area in which patients and pharmacists have differing perceptions. 
Pharmacists agree more strongly that it is within their role to listen to patients when they 
have questions regarding medication. Patients agree more strongly that it is within the 
5 
role of the pharmacist to say “hello” to patients when they visit the pharmacy. This 
suggests a current lack of relationship between pharmacists and patients. The 
development of a professional relationship between pharmacists and patients could 
improve patients’ trust of pharmacists and generate loyalty. 
 
The responsible behavior role of the pharmacist, involving showing an interest in 
working with patients to meet their healthcare needs, communicating a desire to help 
patients manage their medication, and making sure that patients understand how to use 
their medications before leaving the pharmacy also suggests differing perceptions of the 
pharmacists’ role. In each of these three cases, pharmacists show stronger agreement with 
these aspects of responsible behavior. The reason for differing perceptions may simply 
arise from the fact that patients are unaware the pharmacist can offer these services. 
However, the differing ideas could also be due to the fact that patients perceive these 
roles as belonging to physicians or other practitioners, rather than a community 
pharmacist. This is the area in which pharmacists can improve their position and 
perceived role as healthcare team members. In order to adopt a more involved and 
expanded role in healthcare, pharmacists could allot more dispensing responsibilities to 
pharmacy technicians and participate in more face-to-face contact with patients through 
offering more immunizations, adopting medication management programs, and 
performing rapid diagnostic tests.  
 
A professional relationship between pharmacists and patients can create loyalty and trust. 
Approximately 74% of patient respondents reported they did not have a professional 
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relationship with their pharmacist to manage their medications (Worley et al., 2007). Of 
the respondents that did report having professional relationships with their pharmacists, 
the average length of the relationship was 7.6 years. By instigating a professional 
relationship with patients, pharmacists can gain trust, loyal customers (which is good for 
business and profit), and can better help their patients. Gaining trust could help 
pharmacists to successfully offer rapid diagnostic tests, as patients are more likely to look 
to pharmacists for healthcare needs if they have proved over several years that they are 
capable experts in their area. Pharmacists could better help patients if the two are 
engaged in a professional relationship, as pharmacists would be aware of all medications 
the patient is taking and would also be knowledgeable of the patient’s medical history. 
 
Differing perceptions of the role of the pharmacist could be a barrier to the adoption of 
rapid diagnostic tests in community pharmacies, as patients may not view anything 
beyond dispensing as the pharmacist’s role. However, this barrier would not be difficult 
to overcome. If pharmacists could assign more dispensing duties to pharmacy 
technicians, heavily market the services offered at the pharmacy, and spend more time 
engaging with patients, the perceptions patients have of pharmacists could change 
drastically and shift from that of the pharmacist as a medication dispenser to that of the 
pharmacist as a front-line healthcare professional. 
 
Pharmacy Services and RDTs 
Within the past decade, pharmacists have adopted the role of immunizer in many 
community pharmacies. Like RDTs, immunization services represent a shift in the role of 
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the pharmacist from medication dispenser to healthcare provider. Not surprisingly, there 
were many perceived barriers to the adoption of immunization services.  
 
Khalid M. Kamal and colleagues (2003) investigated pharmacists’ participation in and 
impact on immunization services. Respondents overall showed a strong willingness to 
counsel and promote immunizations, while many were less willing to actually administer 
vaccines. The reluctance to administer vaccines stems from the many factors pharmacists 
perceived problematic to the provision of immunization. The major barriers identified 
included the availability of physicians who agree pharmacists should offer 
immunizations, the availability of space within the pharmacy, the availability of time, 
staff support, level of reimbursement, and concern about legal liability. Many of these 
barriers remained present years later, as was portrayed in another study conducted in 
2008. 
 
In 2008, Gretchen L. Kummer and Leigh L. Foushee conducted a study focused on 
pharmacy immunization services in North Carolina. 1, 274 pharmacists were surveyed, 
whether they were active immunizers, inactive immunizers, or nonimmunizers. All 
respondents were likely to perceive time and space as potential barriers to immunization 
services. Other perceived barriers included the availability of vaccines, obtaining 
reimbursement from third-party providers, the state’s regulations on pharmacist-
administered immunizations, and the availability of physician support.  
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Despite the perceived barriers to adopting immunization services pharmacists anticipated, 
immunization services were adopted in many pharmacies nationwide. The adoption of 
immunization services closely parallels the adoption of RDTs, as both are services that 
have not historically been offered by pharmacies and have not been perceived as 
belonging in pharmacies prior to implementation. The barriers to adopting RDTs will be 
further investigated in this study, but are likely to include the barriers pharmacists 
identified in regards to immunization services, namely the availability of time, space, and 
physician support. 
 
RDT Policies 
Obvious problems arise when considering the expanding role of the pharmacist and the 
effect on other healthcare providers. Such problems are addressed in Collaborative 
Practice Agreements (CPA), formal agreements in which a licensed provider makes a 
diagnosis, supervises patient care, and refers patients to a pharmacist under a protocol 
that allows the pharmacist to perform specific patient care functions (CDC, 2013).  CPAs 
give pharmacists the ability and authority to act in the best interest of the patient as part 
of a healthcare team. The CDC lists medication therapy management, collaborative drug 
therapy management, immunizations, counseling, diabetes management services, and 
blood pressure and cholesterol monitoring as services made possible in the pharmacy due 
to CPAs between pharmacists and healthcare providers.  
 
Performing RDTs in the pharmacy would require CPAs between pharmacists and 
physicians. Whilst CPAs require pharmacists to seek out local healthcare providers and 
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form agreements, they can ultimately reduce patient fragmentation of care and improve 
health outcomes.  
 
Rapid diagnostic testing in pharmacies is more relevant an issue now than ever. The 
following policies were adopted by the American Pharmacists Association’s House of 
Delegates at the 2016 APhA Annual Meeting in regards to rapid diagnostic testing: 
1. APhA recognizes the value of pharmacist-provided, point-of-care testing and  
related clinical services, and it promotes the provision of those tests and services 
in accordance with the Joint Commission of Pharmacy Practitioners Pharmacists’ 
Patient Care Process.  
2. APhA advocates for laws, regulations, and policies that enable pharmacist-
provided, point-of-care testing, and related clinical services that are consistent 
with the pharmacists’ role in team-based care.  
3. APhA opposes laws, regulations, and policies that create barriers to the tests 
that have been waived by the Clinical Laboratory Improvement Amendments and 
that are administered and interpreted by pharmacists.  
4. APhA encourages the use of educational programming and resources to 
facilitate practice implementation of pharmacist-provided, point-of-care testing 
and related clinical services.  
5. APhA supports patients taking active roles in the management of their health, 
including their ability to request and obtain pharmacist-provided, point-of-care 
tests and related clinical services.  
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6. APhA advocates for access to, coverage of, and payment for both pharmacist-
provided, point-of-care tests and any related clinical services. (American 
Pharmacists Association, 2016) 
 
RDTs in Community Pharmacy 
In some areas of the United States, rapid diagnostic testing in community pharmacies is 
already a reality. In the February 2016 edition of PharmacyToday, Sonya Collins 
investigates the logistics and outcomes of offering RDTs in Hy-Vee pharmacies with 
Alison Kingston, Pharm.D.. In Omaha, Nebraska, Hy-Vee grocery store pharmacies offer 
Group A strep tests and influenza tests as the result of a successful program implemented 
by the University of Nebraska Medical Center and Ferris State University in January 
2014. The logistics of implementation include requiring the pharmacies to register as 
Clinical Laboratory Improvement Amendments (CLIA)-waived laboratories and 
requiring the pharmacies to form Collaborative Practice Agreements (CPAs) with 
prescribers. To register as a CLIA-waived laboratory, pharmacies must file a form with 
the Centers of Medicare and Medicaid Services (CMS). There is no requirement that 
pharmacists receive additional training; however, the National Association of Chain Drug 
Stores (NACDS) does offer a 20-hour Point of Care Testing Certificate for interested 
employers and pharmacists. Pharmacists collect samples from patients, including throat 
swabs for Group A strep and nasal swabs for influenza. For positive screenings, 
pharmacists are authorized through their CPAs to prescribe amoxicillin, azithromycin, or 
oseltamivir. For negative results, pharmacists recommend over-the-counter products as 
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needed to treat symptoms. Test results are sent to the patient’s primary care provider and 
pharmacists follow up with patients two days after tests are performed. 
 
Since the implementation of RDTs in Hy-Vee pharmacies in Omaha, pharmacists have 
helped shorten the time between the onset of influenza symptoms and treatment (thus 
decreasing the spread of infection), strengthened patient-pharmacist relationships, 
witnessed increased patient loyalty, expanded their roles as healthcare providers, and 
experienced a sense of satisfaction, as they can now care for patients in more ways. 
 
The offering of Group A strep and influenza tests in Hy-Vee grocery store pharmacies is 
the result of a successful program implemented by the University of Nebraska Medical 
Center and Ferris State University in January 2014. This program/study was conducted 
by the University of Nebraska Medical Center and Ferris State University from October 
1, 2013, to May 30, 2014, and was published in the Journal of the American Pharmacists 
Association in 2016. The study, titled, “Effectiveness of a pharmacist-physician 
collaborative program to manage influenza-like illness,” (Klepser et al., 2016) 
investigated the implementation of influenza RDTs in community pharmacies in 
Michigan, Minnesota, and Nebraska. All pharmacies possessed a CLIA certificate of 
waiver, as was true with the Hy-Vee pharmacies in PharmacyToday. Pharmacists in 
Klepser and colleagues’ (2016) study also completed a 20-hour Point of Care testing 
certificate course.  
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Pharmacists were required to partner with physicians in one of two ways. Pharmacies 
could serve as CPA sites or prescriber consultation sites. At CPA sites, the pharmacist 
could dispense the appropriate medication in accordance with established CPAs. If 
assessment in accordance with the CPA determined the patient to be clinically unstable, 
the pharmacist called the patient’s primary care provider to discuss appropriate referral. If 
patients did not have a primary care provider, they were referred to urgent care facilities 
or emergency rooms. Encounter summaries were generated from each patient’s visit and 
were sent to either the patient’s primary care providers or the collaborating physician. At 
prescriber consultation sites, the pharmacist would contact the patient’s primary care 
provider and identify a treatment plan, whether that be dispensing an antiviral, scheduling 
an office visit, referral to an emergency department or urgent care center, or treating 
symptoms.  
 
Results from Klepser and colleagues’ (2016) study showed rapid diagnostic testing in 
community pharmacies was time-efficient (the average pharmacy visit was 30-40 
minutes), convenient for patients (as many pharmacies in the study were open 24 hours a 
day, 7 days a week), cost-effective (as the average emergency room visit is $510-635), 
and decreased the unnecessary use of antibiotics (as patients often pressure physicians but 
this is not possible with CPAs).  
 
RDT: HIV 
In the summer of 2012, the FDA approved the rapid HIV test for over-the-counter (OTC) 
sale. Recognizing this movement as an opportunity for community pharmacists to serve 
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as point-of-care providers, Beth E. Meyerson and colleagues (2013) conducted a study in 
Indiana regarding community pharmacists’ attitudes and perceptions about the OTC sale 
of HIV tests. Of the seventeen pharmacists surveyed, only two had experience with HIV 
testing within their pharmacies. Despite the fact that the other fifteen pharmacists were 
unaware of the availability of the test, all seventeen pharmacists recognized the test as an 
opportunity for pharmacists to provide consultation and linkage-to-care.  
 
The HIV rapid test differs from other RDTs (such as Hepatitis C, influenza, and Group A 
streptococcus) in that the test can be interpreted by the patient at home (hence its sale as 
an OTC product). Problems that pharmacists recognized revolved around the fact that the 
test can be purchased and then performed and interpreted at home, with no need for the 
patient to return to the pharmacy. Pharmacists were not comfortable with just selling the 
test and having patients leave the pharmacy (Meyerson et al., 2013). In the case of the 
rapid OTC HIV test, pharmacists felt that consultation regarding test results and linkage 
to HIV treatment were equally important. The placement of the HIV test within the 
pharmacy was also an area of uncertainty. This uncertainty directly relates to the 
pharmacists’ concern regarding the lack of consultation patients purchasing the test may 
be receiving. The sale of the test behind the counter offers pharmacists a definite 
opportunity to provide consultation during the point-of-sale, whereas the sale of the test 
out in the store risks the chance of the patient purchasing the test without pharmacists’ 
knowledge. As consultation is a definite concern, the sale of the test behind the counter 
seems favorable. However, for patients purchasing the test for others or those concerned 
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with being discrete, the sale of the test behind the counter may prevent purchases and 
ultimately result in fewer people learning their HIV status early. 
 
Despite the concerns of pharmacists regarding the rapid OTC HIV test, including its 
placement in the pharmacy and patient consultation barriers, all pharmacists recognized 
the sale of the test as an opportunity for pharmacists to offer consultation and linkage to 
care. Pharmacists in the Indiana-based study were willing to provide consultation and 
linkage to care in order to best help patients, which provides encouraging evidence for 
the implementation of other RDTs in the community pharmacy. The image of the 
pharmacist as a health consultant is consistent with a pharmacy practice shift from the 
isolated druggist to healthcare team member, immunizer, medication consultant, and even 
tester (Meyerson et al., 2013). 
 
The pharmacist is considered a trusted and highly educated professional, so perhaps it 
should not be surprising that pharmacists are adopting more responsibilities and roles as 
healthcare team members rather than solely remaining the dispensers of medication when 
called for by a physician. 
 
RDTs and the Diffusion of Innovations 
Pharmacists’ perceptions of the offering of RDTs in the community pharmacy setting can 
be investigated using Everett M. Rogers’ diffusion of innovations theory, in which, 
“Diffusion is the process by which (1) an innovation (2) is communicated through certain 
channels (3) over time (4) among the members of a social system” (Rogers, 2014). The 
15 
diffusion of innovations theory seeks to explain how an innovation is adopted and 
implemented. There are four key elements to the theory: the innovation, communication 
channel, time, and social system. This study revolves around the innovation (rapid 
diagnostic testing in community pharmacies) and its attributes (including relative 
advantage, compatibility, complexity, trialability, and observability). 
 
The innovation is an idea, practice, or object that is perceived as new by an individual or 
other unit of adoption. In the case of the implementation of RDTs, rapid diagnostic 
testing in community pharmacies is the innovation. Innovations have several perceived 
attributes, including their relative advantage, compatibility, complexity, trialability, and 
observability. An innovation’s relative advantage is the degree to which an innovation is 
perceived as better than the idea it supersedes. The relative advantage of RDTs is the 
comparison of offering RDTs versus not offering RDTs, and factors such as economic 
terms, convenience, satisfaction, and advantageousness can all contribute. An 
innovation’s compatibility is the degree to which an innovation is perceived as being 
consistent with the existing values, past experiences, and needs of potential adopters. The 
more compatible an innovation is, the more rapidly it will be adopted. Compatibility 
concerns that arise from offering RDTs in pharmacies include time constraints and the 
availability of space in the pharmacy to perform and interpret RDTs. An innovation’s 
complexity is the degree to which an innovation is perceived as difficult to understand 
and use. Innovations simpler to understand are adopted more quickly than their more 
complex counterparts, which may require the adopter to develop new skills and 
understanding. The pharmacists’ preparedness and knowledge of RDTs could serve as 
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complexity concerns, as a pharmacist who has had curriculum covering the performance 
and interpretation of RDTs may be more readily prepared and willing to offer RDTs than 
a pharmacist who must first participate in a continuing education program (Akinwale et 
al., 2015). An innovation’s trialability is the degree to which an innovation may be 
experimented with on a limited basis. Innovations that can be tested and trialed before 
being permanently implemented will be adopted more quickly than those that are not 
divisible, the reason being that a trialable innovation represents less uncertainty to 
adopters. A pharmacy’s ability to experiment with giving RDTs before permanently 
adopting the service is therefore important in the adoption of RDTs as a pharmacy-based 
service. An innovation’s observability is the degree to which the results of an innovation 
are visible to others. For example, community pharmacies may adopt RDTs more quickly 
if pharmacies in the nearby area are offering them. The attributes of an innovation are of 
the utmost importance to this study, as RDTs are a service not yet typically offered in 
pharmacies.  
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METHODOLOGY 
Purpose and Objectives 
The broad purpose of this study is to describe community pharmacists’ perceptions of 
RDTs in community pharmacies in Mississippi. 
 
The focused goal of this study is to determine the correlation between Everett M. Rogers’ 
attributes of the diffusion of innovations (including relative advantage, compatibility, 
complexity, trialability, and observability) and the willingness of community pharmacists 
to offer RDTs in community pharmacies in Mississippi. 
 
Rapid Diagnostic Tests (RDTs) were referred to as Point of Care tests in all aspects of 
communication with participants, including both in the email invitation and throughout 
the survey. Point of Care testing was the terminology chosen over RDTs due to the 
possible negative connotation of the word “diagnostic.” In order to best present Point of 
Care testing to participants, the word “diagnose” was not utilized at all during 
communication with participants. The RDTs of consideration for this study were 
Influenza, Group A Strep, Hepatitis C, and HIV, as the average community pharmacist is 
likely familiar with at least one of these conditions and the appropriate treatment(s). For 
this study, pharmacists were told, “Point of Care testing involves performing a robust test 
outside of a laboratory near the patient to provide a reliable result to aid in disease 
screening. The following survey investigates perceptions of Point of Care testing in 
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community pharmacies for infections including Influenza, Group A Strep, Hepatitis C, 
and HIV.” 
 
Sample 
A list of licensed pharmacists (study participants) in the state of Mississippi was obtained 
from the Mississippi Board of Pharmacy in 2015. A screening question was included 
ensuring participants had practiced in a community pharmacy in Mississippi within the 
year prior to taking the survey. Thus, the sample includes registered pharmacists in the 
state of Mississippi who had experience working in a community pharmacy within the 
year prior to taking the survey. 
 
Data Collection 
An internet-based survey was sent to the potential participants using an electronic 
platform, Qualtrics®, along with an email invitation, which is included in Appendix A, in 
2016. A screening question was included to ensure all participating pharmacists had 
recent community pharmacy experience. The invitation included information about the 
study and a link to the survey. All potential participants were informed that the survey 
was voluntary and answers would be kept confidential. Potential respondents were sent 
two email invitations. 
 
Survey Instrument 
The survey sent to participants is included in Appendix B. It consisted of six sections: 
screening question, demographics, practice setting, diffusion of innovations, benefits and 
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concerns, and willingness to offer Point of Care testing. Participants were sent a survey 
with all of the sections combined and indistinguishable.  
 
The screening question served to ensure all participants had recent experience in a 
community pharmacy in Mississippi from which they could base their responses upon for 
the entirety of the survey.  
 
The demographics section included questions regarding age, gender, highest degree held, 
time since graduation, and whether or not the participant has completed a residency. 
 
The practice setting section included questions regarding the participant’s primary 
practice site (chain, independent, or hospital), practice setting (urban or rural), CE 
(continuing education) related to Point of Care testing, services currently offered by the 
participant’s pharmacy (cholesterol/lipid screening/monitoring, diabetes services, 
immunization services, medication synchronization, medication therapy management, 
Point of Care testing, smoking cessation, and an option for other), and the participant’s 
perceived knowledge of Point of Care testing.  
 
The diffusion of innovations section contained the bulk of the material. This section was 
itself divided into five sections according to Everett M. Rogers’ Diffusion of Innovations 
(2014): relative advantage, compatibility, complexity, trialability, and observability.  The 
different sections and statements are shown in Table 1. More information regarding the 
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attributes of the diffusion of innovations can be found in the “Diffusion of Innovations” 
section of the Introduction. 
 
TABLE 1: DIFFUSION OF INNOVATIONS STATEMENTS 
Relative Advantage 
There is an advantage to offering Point of Care testing. 
Offering Point of Care testing would benefit my pharmacy. 
Offering Point of Care testing would benefit patients. 
Offering Point of Care testing would improve my ability to provide quality patient care. 
Compatibility 
Offering Point of Care testing is compatible with the role of the pharmacist. 
There is time to offer Point of Care testing in my pharmacy. 
There is space to offer Point of Care testing in my pharmacy. 
Complexity 
I am prepared to administer Point of Care tests. 
I am prepared to interpret Point of Care tests. 
I have had an opportunity to learn about Point of Care testing. 
I am comfortable offering Point of Care testing in my pharmacy. 
Overall, I believe that Point of Care testing would be easy to offer. 
Trialability 
The pharmacy where I practice could adopt Point of Care testing. 
It would be difficult to try Point of Care testing in a community pharmacy. 
Physicians would be willing to collaborate with me to try to offer point of care testing in 
my pharmacy. 
Observability 
Pharmacies are offering Point of Care testing. 
Pharmacies within the vicinity of my practice site offer Point of Care testing. 
Pharmacists can easily communicate the benefits of offering Point of Care testing. 
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The benefits and concerns section served to identify potential barriers to the 
implementation of Point of Care testing and the potential benefits of offering Point of 
Care testing. This section included statements regarding participants’ perceptions of Point 
of Care testing, shown in Table 2. 
 
TABLE 2: BENEFITS AND CONCERNS STATEMENTS 
Point of Care testing will become a routine part of community pharmacy. 
Community pharmacies should be offering Point of Care testing. 
Offering Point of Care testing is beyond the scope of pharmacy. 
 
Additionally, participants were allowed to select up to three barriers to and benefits of 
offering Point of Care testing. Potential barriers included: difficulty obtaining 
Collaborative Practice Agreements (CPAs), it is beyond the scope of the pharmacist, it 
would require redesign of the pharmacy, lack of appropriate payment, lack of knowledge 
regarding Point of Care testing, lack of patient interest, lack of space, lack of support 
from pharmacy management, lack of time, meeting federal, state, and/or third-party 
demands, not enough personnel, physician resistance, too complicated, and other, in 
which the participant could list a barrier not mentioned. Potential benefits included: 
expanding the role of the pharmacist, increasing revenue for a pharmacy, it would be 
convenient for patients, it would economically benefit patients, opportunity to collaborate 
with physicians, opportunity to offer better patient care, and other, in which the 
participant could list a benefit not mentioned.  
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The willingness to offer Point of Care testing section gauged participants’ willingness to 
offer Point of Care testing, asked participants which test they would be most likely to 
implement first (Group A Strep, Hepatitis C, HIV, or Influenza), and inquired about 
participants’ interest CE regarding Point of Care testing. 
 
Questions varied in format. Participants were required to write in their age. Some 
questions used multiple-choice type questions, such as those regarding years since 
graduation and primary practice site. Others allowed patients to select all boxes that were 
applicable, such as the benefits and concerns of Point of Care testing. A 5-point Likert 
type scale was used for some questions, in which a rating of “1” indicated participants 
strongly disagreed and a rating of “5” indicated participants strongly agreed. 
 
Analysis 
Analysis was conducted using SPSS®. Data were summarized using frequencies and 
descriptive statistics. A multivariable linear regression was used to examine relationships 
between variables. 
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RESULTS 
An email with study details and a link to the Qualtrics® survey was sent to 3110 licensed 
pharmacists in the state of Mississippi. 227 responses were received and 117 participants 
were eligible for the study, resulting in an actual response rate of 3.8%. Exclusion criteria 
included not meeting the screening criteria (those excluded had not practiced in a 
community pharmacy in Mississippi within the year prior to receiving the survey). 
 
Demographics 
Demographics are summarized in Table 3.
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TABLE 3: DEMOGRAPHICS 
Age in Years 
(Age of eligible participants who provided their age, n=115) 
Mean (±SD) 44.5 (±13.2) 
Median  44 
Gender 
Gender Frequency of Selection 
Female 54.7% 
Male 45.3% 
Degrees Held 
Degree Frequency of Selection 
B.S. 55.6% 
Pharm.D. 53.0% 
Other Graduate Degrees (M.S., M.B.A., 
Ph.D., etc.) 
12.0% 
Time Since Graduation 
Time (in years) Frequency of Selection 
0-10 35.9% 
11-20 23.9% 
21-30 17.1% 
31-40 13.7% 
More than 40 9.4% 
Residency Completion 
Has participant completed a residency? Frequency of Selection 
No 87.2% 
Yes 12.8% 
 
 
Practice Site 
Practice Site characteristics are summarized in Table 4. 
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TABLE 4: PRACTICE SITE  
Primary Community Pharmacy Practice Site 
Practice Site Frequency of Selection 
Chain 53.0% 
Independent 34.2% 
Hospital 6.8% 
Other  
(Academia/clinical pharmacy, closed door, 
hospital employee pharmacy and chain, 
inpatient hospice pharmacy, long-term 
care, supermarket, work site pharmacy) 
6.0% 
Primary Community Pharmacy Practice Site: Chain 
Type of Chain Frequency of Selection 
Traditional (e.g. Walgreens, CVS) 47.5% 
Mass Merchandiser (e.g. Walmart) 42.6% 
Grocery 9.8% 
Practice Setting 
Practice Setting Frequency of Selection 
Rural 71.8% 
Metropolitan (>50,000 people) 28.2% 
Continuing Education 
Has participant completed Continuing 
Education relating to point of care testing 
in the past year? 
Frequency of Selection 
No 80.3% 
Yes 19.7% 
Services Offered 
Service Frequency of Selection 
Immunization Services 82.1% 
Medication Therapy Management (MTM) 
Services 
81.2% 
Medication Synchronization Services 54.7% 
Diabetes services 29.1% 
Smoking Cessation Services 18.8% 
Cholesterol/Lipid Screening/Monitoring 13.7% 
Point of Care Testing 13.7% 
Other  
(Blood pressure testing, compounding, 
genetic screening for selected drugs, 
Harmonyx pharmacogenetic testing, 
obesity management) 
4.3% 
Knowledge of Point of Care Testing  
(on a Likert scale with 1 indicating “No Knowledge” and 5 indicating “Very 
Knowledgeable”) 
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Mean (±SD) 2.55 (±1.28) 
Median 3.00 
 
 
Diffusion of Innovations 
Participants were instructed to rate their level of agreement with several statements on a 
Likert scale, with “1” indicating strongly disagree and “5” indicating strongly agree. 
Statements were included for each of the five attributes of the diffusion of innovations:  
relative advantage, compatibility, complexity, trialability, and observability. Mean and 
median ratings for statements of each attribute of the diffusion of innovations are 
summarized in Table 5. 
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TABLE 5: DIFFUSION OF INNOVATIONS: ATTRIBUTE STATEMENT RATINGS 
Relative Advantage 
Statement Mean Rating (±SD) Median Rating 
There is an advantage to 
offering Point of Care 
testing. 
3.95 (±0.86) 4.00 
Offering Point of Care 
testing would benefit my 
pharmacy. 
3.67 (±0.91) 4.00 
Offering Point of Care 
testing would benefit 
patients. 
4.02 (±0.87) 4.00 
Offering Point of Care 
testing would improve my 
ability to provide quality 
patient care. 
3.79 (±0.99) 4.00 
Compatibility 
Statement Mean Rating (±SD) Median Rating 
Offering Point of Care 
testing is compatible with 
the role of the pharmacist. 
3.74 (±1.08) 4.00 
There is time to offer Point 
of Care testing in my 
pharmacy. 
 
 
2.67 (±1.20)   3.00 
There is space to offer point 
of care testing in my 
pharmacy. 
2.92 (±1.27) 3.00 
Complexity 
Statement Mean Rating (±SD) Median Rating 
I am prepared to administer 
Point of Care tests. 
3.12 (±1.23) 3.00 
I am prepared to interpret 
Point of Care tests. 
3.27 (±1.21) 3.00 
I have had an opportunity to 
learn about Point of Care 
testing. 
2.73 (±1.32) 2.00 
I am comfortable offering 
Point of Care testing in my 
pharmacy. 
3.03 (±1.22) 3.00 
Overall, I believe Point of 
Care testing would be easy 
to offer. 
3.05 (±1.09) 3.00 
Trialability 
Statement Mean Rating (±SD) Median Rating 
The pharmacy where I 3.40 (±1.03) 4.00 
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practice could adopt Point 
of Care testing. 
It would be difficult to try 
Point of Care testing in a 
community pharmacy.* 
3.14 (±1.11) 3.00 
Physicians would be willing 
to collaborate with me to try 
to offer Point of Care 
testing in my pharmacy. 
2.81 (±0.84) 3.00 
Observability 
Statement Mean Rating (±SD) Median Rating 
Pharmacies are offering 
Point of Care testing. 
3.19 (±0.90) 3.00 
Pharmacies within the 
vicinity of my practice site 
offer Point of Care testing. 
2.54 (±1.00) 3.00 
Pharmacists can easily 
communicate the benefits of 
offering Point of Care 
testing. 
3.44 (±0.88) 4.00 
*This question was reverse-coded, such that for each question a rating of “1” indicated 
disagreement/not in favor of Point of Care testing and a rating of “5” indicated 
agreement/in favor of Point of Care testing in community pharmacies. 
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For each attribute, the mean and median ratings of each statement were added together 
and divided by the total number of statements to calculate a mean and median rating. 
Mean and median ratings for each attribute of the diffusion of innovations are 
summarized in Table 6. 
 
TABLE 6: DIFFUSION OF INNOVATIONS: ATTRIBUTE RATINGS 
Attribute Mean Rating (±SD) Median Rating 
Relative Advantage 3.86 (±0.83) 4.00 
Compatibility 3.11(±0.99) 3.00 
Complexity 3.04 (±1.00) 3.00 
Trialability 3.12 (±0.75) 3.00 
Observability 3.06 (±0.64) 3.00 
 
 
Benefits and Concerns 
Participants were instructed to rate their level of agreement with several statements on a 
Likert scale, with “1” indicating strongly disagree and “5” indicating strongly agree. 
Mean and median ratings for each statement are summarized in Table 7. 
 
TABLE 7: BENEFITS AND CONCERNS: STATEMENT RATINGS 
Statement Mean Rating (±SD) Median Rating 
Point of Care testing will 
become a routine part of 
community pharmacy. 
3.15 (±0.90) 3.00 
Community pharmacies 
should be offering Point of 
Care testing. 
3.32 (±1.04) 3.00 
Offering Point of Care 
testing is beyond the scope 
of pharmacy.* 
3.69 (±1.14) 4.00 
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*This question was reverse-coded, such that for each question a rating of “1” indicated 
disagreement/not in favor of Point of Care testing and a rating of “5” indicated 
agreement/in favor of Point of Care testing in community pharmacies. 
 
 
Participants were asked to identify up to three primary barriers to offering Point of Care 
testing in pharmacies. Identified barriers are summarized in Table 8. 
 
TABLE 8: BARRIERS TO OFFERING POINT OF CARE TESTING 
Barrier Frequency of Selection 
Lack of time 61.5% 
Difficulty obtaining Collaborative Practice 
Agreements (CPAs) 
32.5% 
Lack of appropriate payment 32.5% 
Not enough personnel 31.6% 
Lack of knowledge regarding Point of Care 
testing 
26.5% 
Meeting federal, state, and/or third-party 
demands 
21.4% 
Lack of space 14.5% 
Physician resistance 14.5% 
It would require redesign of the pharmacy 12.8% 
Lack of patient interest 9.4% 
Lack of support from pharmacy 
management 
7.7% 
It is beyond the scope of the pharmacist 6.0% 
Too complicated 5.1% 
Other  
(Beyond the scope of community pharmacy 
and our service setting, not understanding 
what Point of Care refers to, Point of Care 
testing needs to be done in the home and 
the belief that the home is where all care 
will be in the future, not being aware of 
Point of Care testing, Point of Care devices 
require standardization, accuracy, and 
quality assurance) 
4.3% 
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Participants were asked to identify up to three primary benefits of offering Point of Care 
testing in pharmacies. Identified benefits are summarized in Table 9. 
 
TABLE 9: BENEFITS OF OFFERING POINT OF CARE TESTING 
Benefit Frequency of Selection 
Opportunity to offer better patient care 68.4% 
Expanding the role of the pharmacist 64.1% 
It would be convenient for patients 50.4% 
Increasing revenue for a pharmacy 37.6% 
It would economically benefit patients 21.4% 
Opportunity to collaborate with physicians 16.2% 
Other  
(None, being against Point of Care testing, 
economically benefitting the pharmacy but 
not necessarily the pharmacists, not being 
sure what Point of Care testing entails) 
2.6% 
 
 
Willingness to Offer Point of Care Testing 
Results from willingness to offer Point of Care testing are summarized in Table 10. 
 
TABLE 10: WILLINGNESS TO OFFER POINT OF CARE TESTING 
Willingness to Offer Point of Care Testing in a Community Pharmacy 
(on a Likert scale with “1” indicating Not Willing and “5” indicating Extremely Willing) 
Mean (±SD) 3.40 (±1.29) 
Median 4.00 
Point of Care Test Most Likely to be Implemented First 
Point of Care Test Frequency of Selection 
Influenza 77.2% 
Group A Strep 14.0% 
HIV 6.1% 
Hepatitis C 2.6% 
Interest in Attending a Continuing Education Session on Point of Care Testing 
 Frequency of Selection 
Interested 72.6% 
Not Interested 27.4% 
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Regression Analysis 
Mean ratings for each attribute of the Diffusion of Innovations and for willingness to 
offer Point of Care testing were treated as continuous data for the purpose of analysis. 
 
A linear regression with each attribute of the Diffusion of Innovations as independent 
variables/predictors (the mean ratings for each attribute) and willingness to offer Point of 
Care testing as the dependent variable/outcome variable (the mean rating) was performed. 
Results are summarized in Table 11. 
 
TABLE 11: REGRESSION COEFFICIENTS 
Model 
Unstandardized 
Coefficients 
Standardize
d 
Coefficients 
t Sig. 
95.0% Confidence Interval 
for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
1 (Constant) -1.066 .497  -2.145 .034 -2.052 -.081 
RelativeAdvant
age 
.272 .117 .175 2.312 .023 .039 .504 
Compatibility .141 .123 .108 1.147 .254 -.102 .384 
Complexity .436 .114 .338 3.827 .000 .210 .662 
Trialability .656 .131 .381 5.008 .000 .396 .916 
Observability -.127 .133 -.063 -.957 .341 -.390 .136 
a. Dependent Variable: Rate your willingness to offer Point of Care testing in a community pharmacy, with 1 being 
Not Wi... 
 
33 
A linear regression was performed and values for beta were obtained (unadjusted and 
adjusted for the other predictors). T tests were performed with an alpha of 0.05. 
Confidence intervals were constructed as well. When testing for zero slope (Beta=0) for 
each of the attributes of the diffusion of innovations at the 0.05 level of significance, the 
null hypothesis that Beta=0 was rejected for relative advantage, complexity, and 
trialability.  
 
It can be concluded with 95% confidence that the true slope of the line relating relative 
advantage to willingness to offer Point of Care testing is somewhere between 0.039 and 
0.504. Because 0 is not contained, the null hypotheses that beta=0 is rejected, and as the 
mean relative advantage rating increases by 1, the mean willingness to offer Point of Care 
testing rating increases by 0.039 to 0.504. A higher relative advantage mean rating 
indicates a higher degree to which offering Point of Care testing is perceived as better 
than not offering Point of Care testing, and as the mean relative advantage rating 
increases, so does pharmacists’ willingness to offer Point of Care testing.  
 
It can be concluded with 95% confidence that the true slope of the line relating 
complexity to willingness to offer Point of Care testing is somewhere between 0.210 and 
0.662. Because 0 is not contained, the null hypotheses that beta=0 is rejected, and as the 
mean complexity rating increases by 1, the mean willingness to offer Point of Care 
testing rating increases by 0.210 to 0.662. A higher complexity mean rating indicates one 
is more in agreement with/in favor of offering Point of Care testing in the community 
pharmacy. However, an innovation’s complexity is the degree to which an innovation is 
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perceived as difficult to understand and use, and more complex innovations are adopted 
more slowly. In this survey, complexity was coded such that a higher mean rating was 
associated with less complexity, and the higher the complexity mean rating, the lower the 
complexity of the innovation. Thus, as the complexity mean rating increases and the 
complexity of the innovation decreases, pharmacists’ willingness to offer Point of Care 
testing increases. 
 
It can be concluded with 95% confidence that the true slope of the line relating trialability 
to willingness to offer Point of Care testing is somewhere between 0.396 and 0.916. 
Because 0 is not contained, the null hypotheses that beta=0 is rejected, and as the mean 
trialability rating increases by 1, the mean willingness to offer Point of Care testing rating 
increases by 0.396 to 0.916. A higher trialability mean rating indicates a higher degree to 
which an innovation may be experimented with on a limited basis, and innovations that 
can be tested and trialed before being permanently implemented will be adopted more 
quickly than those that are not. As the trialability mean rating increases, so does 
pharmacists’ willingness to offer Point of Care testing. 
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DISCUSSION 
Diffusion of Innovations 
The mean ratings for each of the attributes of the diffusion of innovations (relative 
advantage, compatibility, complexity, trialability, and observability) were found to be 
3.86 (±0.83), 3.11 (±0.99), 3.04 (±1.00), 3.12 (±0.75), and 3.06 (±0.64), respectively. 
Many responses to statements were neutral as is reflected in the near neutral mean 
ratings. Reasons for the near-neutral mean ratings of the attributes can be explained by 
those statements which generated mean ratings of less than 3, which indicate 
disagreement/not in favor of Point of Care testing. Statement mean ratings of less than 3 
existed for the following attributes: compatibility, complexity, trialability, and 
observability. The statements that generated mean ratings of less than 3 are summarized 
in Table 12. 
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TABLE 12: DIFFUSION OF INNOVATIONS: STATEMENTS GENERATING MEAN 
RATINGS OF LESS THAN 3 
Statement Mean Rating (±SD) 
There is time to offer Point of Care testing 
in my pharmacy. 
2.67 (±1.20) 
There is space to offer Point of Care testing 
in my pharmacy. 
2.92 (±1.27) 
I have had an opportunity to learn about 
Point of Care testing. 
2.73 (±1.32) 
 Physicians would be willing to collaborate 
with me to try to offer Point of Care testing 
in my pharmacy. 
2.81 (±0.84) 
Pharmacies within the vicinity of my 
practice site offer Point of Care testing. 
2.54 (±1.00) 
 
One reason for near-neutral mean ratings of attributes could be the fact that many 
participants are waiting for higher management to implement the changes necessary for 
Point of Care testing. Lack of time, space, and education regarding Point of Care testing 
can be attributed to higher management. Lack of time and space are issues that require 
redesign of the workflow and the pharmacy, respectively. As only 34.2% of participants 
selected their primary community pharmacy practice site as “independent,” the other 
65.8% of participants likely work under the direction of higher management, and 
redesign of the workflow and the pharmacy is not likely within the scope of these 
participants’ duties and responsibilities. Lack of learning about Point of Care testing can 
also be attributed to higher management for participants working in areas of community 
pharmacy other than independent pharmacy. In order for pharmacists to offer Point of 
Care testing, a certain level of education is required. Education is often provided by 
higher management in the form of Continuing Education. Pharmacists must learn about 
Point of Care testing in the form of Continuing Education in order to offer Point of Care 
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testing, and higher management must therefore provide Continuing Education to 
pharmacists if they are to offer Point of Care testing. If higher management can 
implement these changes (redesign of the workflow, redesign of the pharmacy, and 
availability of Continuing Education courses on Point of Care testing), pharmacists may 
be more strongly in agreement with offering Point of Care testing.  
 
Another reason for near-neutral mean ratings of attributes could be lack of support from 
the healthcare community. Participants indicated they disagreed physicians would be 
willing to collaborate with pharmacists. Without physician collaboration, Point of Care 
testing is not possible, as there is a need for Collaborative Practice Agreements or at least 
consultation. This lack of willingness of physicians could cause participants to have 
neutral opinions regarding Point of Care testing. Even if there are clear benefits to 
offering Point of Care testing, without physician collaboration Point of Care testing 
cannot become a reality. Since Point of Care testing is not possible in this situation, it is 
likely to generate less agreement among participants, thus leading to near-neutral mean 
ratings. 
 
Near neutral mean ratings of attributes could also be explained by a current lack of 
consideration of implementing Point of Care testing. Participants indicated they disagreed 
pharmacies within the vicinity of their practice sites offer Point of Care testing. If Point 
of Care testing is not offered by pharmacies in the vicinity, or by competitors, there is 
little perceived need to implement Point of Care testing. Therefore, even if participants 
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believe Point of Care testing is beneficial, if there is no perceived need to adopt Point of 
Care testing, there may be less agreement and therefore near-neutral mean ratings. 
 
Benefits and Concerns 
The top five barriers to offering Point of Care testing recognized by participants include 
(in order of frequency of selection from highest to lowest): lack of time, difficulty 
obtaining Collaborative Practice Agreements (CPAs), lack of appropriate payment, not 
enough personnel, and lack of knowledge. Of these five barriers, only one is directly 
related to the pharmacist. Lack of time and personnel can be attributed to higher 
management, as these problems can be solved with redesign of the workflow and changes 
in staffing. For the 65.8% of participants who do not work primarily in independent 
community pharmacy, the responsibility of eliminating these barriers belongs to higher 
management.  Difficulty obtaining Collaborative Practice Agreements (CPAs) and lack 
of appropriate payment are barriers attributed to other healthcare professionals and third-
party payers. Lack of knowledge is the only barrier identified by participants that can be 
attributed to and solved by participants themselves. Participants who feel they lack 
knowledge can seek out learning opportunities, possibly through nearby schools of 
pharmacy or through Continuing Education. However, even this lack of knowledge could 
also be attributed to higher management. Pharmacists under the direction of higher 
management must learn about Point of Care testing in the form of Continuing Education 
in order to offer Point of Care testing, and higher management must therefore provide 
Continuing Education to pharmacists if they are to offer Point of Care testing. Thus, only 
one of the top five barriers to offering Point of Care testing is directly related to the 
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participant, and this one barrier can in many cases still be attributed to higher 
management. 
 
The top five benefits of offering Point of Care testing recognized by participants include 
(in order of frequency of selection from highest to lowest): opportunity to offer better 
patient care, expanding the role of the pharmacist, it would be convenient for patients, 
increasing revenue for a pharmacy, and it would economically benefit patients.  
 
Limitations 
This study lacks external validity; it investigated only the perceptions of pharmacists who 
practice community pharmacy in Mississippi. Perceptions among pharmacists could 
differ between states.  
 
This study worked with a convenience sample not representative of the entire population 
of community pharmacists in Mississippi. Any pharmacist in Mississippi who met the 
screening criteria (i.e. had practiced in a community pharmacy in Mississippi within the 
year prior to receiving the survey) could participate. The repercussions of convenience 
sampling are reflected in several areas of this study, including the offering of clinical 
services by community pharmacies, time since graduation with most recent degree, 
practice setting (rural or metropolitan), residency completion, and CE completion. 
 
The majority of participants’ community pharmacies offered immunization services 
(82.1%), Medication Therapy Management (MTM) services (81.2%), and/or medication 
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synchronization services (54.7%). The offering of clinical services could influence one’s 
willingness to offer Point of Care testing, as the adoption of a new service may not be a 
foreign concept to these individuals. For new services to be offered, the pharmacy design, 
pharmacy workflow, and billing of services must be considered. It may therefore be more 
feasible for pharmacies that currently offer/have offered services to implement Point of 
Care testing. It may also be more feasible for pharmacists who have offered services 
before to implement Point of Care testing. In order to offer services, training and 
education is required. Pharmacists who are frequently trained and educated may find 
Point of Care testing less intimidating, and thus may be more willing to offer Point of 
Care testing. Had the majority of participants’ community pharmacies not offered 
services, perhaps the mean rating for willingness to offer Point of Care testing would 
have been lower than 3.40 (±1.29). 
 
More than one-third of participants in this study graduated with their most recent degree 
0-10 years ago (35.9%). This could be a limitation of this study, as there are certainly 
practicing pharmacists in the state who graduated more than 10 years ago. In 2008, the 
University of Mississippi School of Pharmacy faculty revised the curriculum to better 
prepare students to provide patient-centered care and to ensure that patients achieve 
optimal outcomes of their medication therapy (The University of Mississippi School of 
Pharmacy). Curricula produce pharmacists, and different curricula with different 
emphases can produce pharmacists with different strengths and skills. Thus, participants 
who graduated with different curricula have different skillsets and strengths, and perhaps 
the participants of this study who graduated within the past 10 years believe they are 
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capable and willing to offer Point of Care testing while the participants who graduated 
more than 10 years ago believe they are less capable and less willing. Perhaps if fewer 
participants graduated within the past 10 years, the mean rating for willingness to offer 
Point of Care testing would have been lower than 3.40 (±1.29). 
 
71.8% of participants in this study practice pharmacy in rural areas. Rural areas lack the 
multitude of healthcare facilities and providers present in urban/metropolitan areas. In 
some rural towns, there may be but one family physician. It is in the best interest of both 
healthcare providers and patients that Point of Care testing is offered in community 
pharmacies in rural areas. By offering Point of Care testing, pharmacists would be 
helping to relieve physicians of some of the workload associated with being one of a few 
physicians in an area. In this way, physicians in rural areas may be more willing to work 
with pharmacists, as they are benefiting from the implementation of Point of Care testing 
in community pharmacies. Additionally, the availability of Point of Care tests in 
community pharmacies would expand access to healthcare services for much of the rural 
population, thus eliminating some of the health disparities that are known to exist in rural 
areas. Pharmacists in urban/metropolitan areas may not see the need for Point of Care 
testing in the community pharmacy, and physicians in urban/metropolitan areas may not 
be willing to surrender those services to pharmacists. 
 
Few participants completed residencies (12.8%) and thus few participants had the 
additional training and knowledge gained by completing a residency. Additionally, 
19.7% of participants completed Continuing Education (CE) related to Point of Care 
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testing in the past year while 80.3% did not. The lack of residency experience and lack of 
CE completion may have contributed to the low mean rating of knowledge of Point of 
Care testing of 2.55 (±1.28).  
 
This study does not aim to investigate the likelihood of the implementation of Point of 
Care testing in the community pharmacy but rather the pharmacists’ perceptions of such. 
Pharmacists’ perceptions are not the sole determinant of whether Point of Care testing 
will be implemented in pharmacies. Patients must see a benefit and a need, as well. To 
get a better idea of the likelihood of the implementation of Point of Care testing in 
community pharmacies, patients should be surveyed regarding their perceptions of Point 
of Care testing in the community pharmacy. 
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CONCLUSION 
The attributes of Rogers’ diffusion of innovations that influence Mississippi pharmacists’ 
willingness to offer RDTs in the community pharmacy include relative advantage, 
complexity, and trialability. As the perceived benefit increases, perceived complexity 
decreases, and degree to which an innovation may be experimented with on a limited 
basis increases, a Mississippi community pharmacist’s willingness to offer RDTs 
increases. As RDTs are more widely implemented in community pharmacies, it will be 
important for pharmacists to see an advantage in offering RDTs, be prepared to 
understand RDTs, and be able to experiment with the implementation of RDTs. 
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APPENDIX A: EMAIL INVITATION 
The Evolution of Community Pharmacy Practice: Investigating the 
Adoption of Point of Care Testing in Community Pharmacies in 
Mississippi 
 
Investigator 
Erin Hoevelmann 
The University of Mississippi School of 
Pharmacy 
Sally McDonnell Barksdale Honors College 
eahoevel@go.olemiss.edu 
Advisor 
Donna West-Strum, Ph.D. 
The University of Mississippi School of 
Pharmacy: Department of Pharmacy 
Administration 
dswest@olemiss.edu 
(662) 915-1071 
 
Dear Participant: 
 
My name is Erin Hoevelmann and I am a pre-pharmacy student at the University of 
Mississippi. As my senior thesis for the Sally McDonnell Barksdale Honors College, I 
am investigating the adoption of Point of Care testing in community pharmacies in 
Mississippi. I am inviting you to participate in this research study by clicking on the 
survey link below and completing the online survey. 
 
The survey will require approximately 10-15 minutes to complete. There is no 
compensation for responding nor is there any known risk. In order to ensure that all 
information will remain anonymous, please do not include your name. If you choose to 
participate in this project, please answer all questions as honestly as possible. 
Participation is strictly voluntary and you may refuse to participate at any time. 
 
Thank you for taking the time to assist me in my educational endeavors. The data 
collected will provide useful information regarding perceptions of Point of Care testing in 
community pharmacies. If you have questions, please feel free to contact me or my 
advisor, Dr. Donna West-Strum, at the email addresses or phone number listed above. 
 
By clicking on the link and participating, you are certifying you are over eighteen years 
of age and have read and understand the above information. Clicking on the link below 
and completing the survey will indicate your willingness to participate in this study. 
 
This study has been reviewed by The University of Mississippi’s Institutional Review 
Board (IRB).  If you have any questions, concerns, or reports regarding your rights as a 
participant of research, please contact the IRB at (662) 915-7482 or irb@olemiss.edu. 
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Sincerely, 
 
Erin Hoevelmann 
UM School of Pharmacy- Early Entry Program 
Sally McDonnell Barksdale Honors College 
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APPENDIX B: QUALTRICS® SURVEY
 
52 
 
53 
 
54 
 
55 
 	
